425: NextCure and Avere Therapeutics Announce Merger

NextCure and Avere Therapeutics have entered into a merger agreement to combine, with Avere's lead drug candidate AVR-001 for inflammatory diseases as a key focus.

Summary

• NextCure, Inc. and Avere Therapeutics, Inc. have agreed to merge, creating a combined entity focused on Avere's drug candidate, AVR-001.
• AVR-001 is a once-weekly oral peptide IL-23 receptor antagonist (IL-23RA) targeting inflammatory conditions like psoriasis, psoriatic arthritis, and inflammatory bowel diseases.
• Phase 1 data for AVR-001 in psoriasis showed encouraging results, including a half-life supporting weekly dosing and improvements in PASI scores and key biomarkers, comparable to existing treatments.
• The merger is structured as a two-step merger involving subsidiaries of NextCure and Avere.
• Avere's management team has a strong track record in drug development and company building, including previous successes at Akero Therapeutics.
• The combined company anticipates financing to support AVR-001 through Phase 2b psoriasis readouts and initiation of Phase 2b ulcerative colitis and Phase 3 psoriasis trials.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, driven by the promising Phase 1 data for AVR-001 and the experienced management team, balanced by the inherent risks of drug development and the need for further clinical validation.

Positives

• AVR-001 demonstrates a half-life supporting once-weekly oral dosing, offering potential convenience over daily oral or injectable therapies.
• Phase 1 data for AVR-001 in psoriasis showed encouraging efficacy, with absolute PASI score reductions and PASI 75 response rates comparable to existing treatments like Icotyde.
• AVR-001 achieved consistent and robust reductions in key biomarkers (IL-17A and hBD-2) in Phase 1 studies, aligning with Icotyde's profile.
• The drug candidate targets validated and effective pathways (IL-23R) in large and growing markets for inflammatory diseases.
• Avere's management team has a proven history of successful drug development and company building, including an IPO and sale of a previous company.
• The combined company's financing is expected to fund AVR-001 through significant clinical milestones, including Phase 2b psoriasis readouts and initiation of Phase 2b UC and Phase 3 psoriasis trials.
• The potential for AVR-001 to address multiple high-value indications (psoriasis, IBD, PsA) presents a significant market opportunity.

Negatives

• The Phase 1 data for AVR-001 is based on cross-trial comparisons with Icotyde, as no head-to-head trials have been conducted.
• Trial designs, patient populations, and endpoints differ between the AVR-001 Phase 1 MAD study and Icotyde's Phase 3 trials, limiting direct comparability.
• One serious adverse event (myocardial infarction) was reported in a Phase 1 patient with multiple cardiovascular risk factors, though deemed unrelated.
• Increased lipase and ALT levels were observed in some AVR-001 cohorts, and increased triglycerides and hyperuricemia were also noted.
• The securities offered in the private placement have not been registered under the Securities Act of 1933, limiting their accessibility and liquidity.
• The merger is subject to customary closing conditions, including stockholder approval and completion of a financing transaction, which may not occur.

Risks

• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including the failure to satisfy closing conditions for the merger or financing.
• Preclinical and clinical data generated by third parties outside the U.S. may not be directly predictive of U.S. clinical trial results or regulatory outcomes.
• The combined company's ability to advance its product candidates and achieve anticipated timelines for clinical trials and regulatory filings is subject to numerous uncertainties.
• There is no assurance that the assumptions or estimates regarding market data and competitive position are accurate.
• The company is under no obligation to update or keep current the information contained in the presentation.
• The drug candidates are under preclinical and/or clinical investigation and have not been approved by the FDA, with no representation made as to their safety or effectiveness.
• Risks associated with the combined company's ability to manage expenses, obtain sufficient capital, and protect its intellectual property rights.

Future Outlook

The combined company aims to advance AVR-001 through key clinical development stages, including Phase 2b trials in psoriasis and ulcerative colitis, and Phase 3 trials in psoriasis, with financing expected to support these milestones. The company anticipates significant market opportunities in psoriasis and inflammatory bowel diseases.

Management Comments

• Icotyde has the potential to be one of our largest products ever.
• Oral IL-23RAs have blockbuster potential.
• Peak psoriasis sales alone are projected to reach >$5B.
• Expansion into IBD and PsA significantly amplifies upside potential.
• Protagonist (PTGX) valued at >$5B, with majority of value potentially driven by Icotyde royalty.
• Icotyde QD dosing, requiring daily fasting, remains a key disadvantage of the recently approved therapy.

Industry Context

StockSavvy.ai notes that the merger between NextCure and Avere Therapeutics positions the combined entity to capitalize on the growing market for IL-23 receptor antagonists in inflammatory diseases. The development of an oral, once-weekly option like AVR-001 addresses a key unmet need for convenience and compliance, potentially disrupting the current landscape dominated by injectables and daily oral therapies.

Comparison to Industry Standards

• AVR-001's Phase 1 data shows absolute PASI score reductions and PASI 75 response rates comparable to Icotyde (JNJ) in Phase 3 trials, despite cross-trial comparison limitations.
• The half-life of AVR-001 (~100 hours) supports once-weekly dosing, a significant convenience factor compared to daily dosing regimens of some oral therapies.
• The IL-23R pathway is a validated target, with significant market penetration by existing therapies like Skyrizi (AbbVie) and Tremfya (Janssen), which generated ~$15B combined in psoriasis in 2025.
• Icotyde (JNJ), the first oral IL-23RA, has validated the oral market potential, with projected peak sales of over $8 billion in psoriasis alone.
• Avere's management team previously led Akero Therapeutics, which successfully navigated from crossover financing through an IPO and eventual sale to Novo Nordisk for up to $5.2 billion.

Legal Proceedings

• The filing mentions that participants in the solicitation of proxies may be deemed participants in the solicitation of proxies from stockholders in connection with the proposed transaction.

Stakeholder Impact

• Shareholders of NextCure will participate in the combined entity, with expected ownership percentages detailed.
• Patients with psoriasis, IBD, and PsA may benefit from a potentially more convenient and effective oral treatment option.
• Investors in the private placement will acquire unregistered securities of Avere, with associated risks and potential rewards.
• Employees of both companies may experience changes related to the integration and future operations of the combined entity.

Next Steps

• Complete the merger transaction between NextCure and Avere.
• Obtain stockholder approval for the merger.
• Complete the pre-closing financing transaction.
• Advance AVR-001 into Phase 2b clinical trials for psoriasis and ulcerative colitis.
• Initiate Phase 3 clinical trials for AVR-001 in psoriasis.
• Conduct China Phase 2b psoriasis readout in 1H 2027.

Key Dates

Recommendation

The merger presents a promising drug candidate with strong Phase 1 data and an experienced team, but significant clinical and regulatory hurdles remain. The outcome of the merger and subsequent clinical trials, along with financing success, will be critical. A 'hold' recommendation reflects the potential upside balanced against the substantial risks inherent in early-stage drug development and M&A integration.

Keywords

NextCure, Avere Therapeutics, Merger, AVR-001, IL-23RA, Psoriasis, Inflammatory Bowel Disease, Biotechnology